Injection of Saa1 inhibitor via caudal vein could effectively inhibit Saa1 and insulin resistance induced by obesity, suggesting that Saa1 inhibitor may be a potentially effective therapeutic strategy for obesity-induced insulin resistance (Fig. 6). The gene discussed is SAA1; the disease is obesity due to melanocortin 4 receptor deficiency.